IL-33 Protein (AA 112-270)

Catalog No. ABIN1096943

Product Details

Target: IL-33 (IL33) (Interleukin 33 (IL33))

Protein Type: Recombinant

Protein Characteristics: AA 112-270

Origin: Human

Source: Escherichia coli (E. coli)

Purpose: Recombinant Human Interleukin-33/IL-33

Sequence: MSITGISPIT EYLASLSTYN DQSITFALED ESYEIYVEDL KKDEKKDKVL LSYYESQHPS NESGDGVDGK MLMVTLSPTK DFWLHANNKE HSVELHKCEK PLPDQAFFVL HNMHSNCVSF ECKTDPGVFI GVKDNHLALI KVDSSENLCT ENILFKLSET

Characteristics:

Recombinant Human Interleukin-33/IL-33

Purity: > 95 % as determined by reducing SDS-PAGE.

Sterility: 0.2 μm filtered

Endotoxin Level: Less than 0.1 ng/μg (1 IEU/μg) as determined by LAL test

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: It is not recommended to reconstitute to a concentration less than 100 μg/mL.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

Buffer: Lyophilized from a 0.2 μm filtered solution of 20 mM TrisHCl, 150 mM NaCl, pH 7.5.

Handling Advice: Always centrifuge tubes before opening. Do not mix by vortex or pipetting.

Storage: 4 °C/-20 °C/-80 °C

Storage Comment: Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Target Details

Target: IL-33 (IL33) (Interleukin 33 (IL33))

Alternative Name: Interleukin-33/IL-33 (IL33 Products)

Background: Recombinant Human Interleukin-33/IL-33 is produced with our E. coli expression system. The target protein is expressed with sequence (Ser112-Thr270) of Human IL-33.
Interleukin-33 (IL-33) was initially discovered as a nuclear factor NF-HEV abundantly expressed in high endothelial venules. It is a 30-32 kDa pro-inflammatory protein with intracellular and extracellular activities and a chromatin-associated cytokine of the IL-1 family with high sequence and structural similarity to IL-1 and IL-18. IL-33 is highly and selectively expressed by high endothelial venule endothelial cells (HEVECs) in human tonsils, Peyers's patches, and lymph nodes. It contains a bipartite nuclear localization signal at the C-terminus, and is targeted to the nucleus when ectopically expressed in human umbilical vein endothelial cells (HUVECs) and HeLa cells. The C-terminal fragment, corresponding to mature IL-33, binds and triggers signaling. IL-33 mediates its biological effects via Toll-interleukin 1 (IL-1) receptor (TIR) domain-containing receptor ST2, activates NF-κB and MAP kinases, and drives production of T(H)2-associated cytokines from in vitro polarized T(H)2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs. Human IL-33 is 270 AAs in length.

Molecular Weight: 20.29 kDa

UniProt: O95760

Pathways: Production of Molecular Mediator of Immune Response